Dante Labs, A Global Leader In Genomics And Precision Medicine, Announced Today That It Has Partnered With The Renato Dulbecco Foundation To Provide More Personalized Therapies For Rare Diseases, Oncology And Covid-19. Protelica, The Innovative Us Biotech Company, Has Licensed Its Library Of Billions Of Pronectin Nanoantibodies And A Portfolio Of 12 Patents To The Renato Dulbecco Foundation. As Part Of The Pharmaceutical Research Collaboration, The Renato Dulbecco Foundation Will Leverage The Dante Platform To Identify Nanoantibodies And Their Efficacy For A Wide Range Of Applications, Including For The Experimental Treatment Of Covid-19 And All Of Its Variants Resistant To Traditional Therapies. And Orphan Diseases. Further R&D Activities Will Be Outsourced To Twist Biosciences."Personalized Medicine Needs Personalized Data, And It Is Through Partnerships Like Ours With The Renato Dulbecco Foundation That We Can Use The Power Of Genomic Information To Treat Disease And Ultimately Deliver Better Health Outcomes For Patients," Stated Andrea Riposati, Ceo Of Dante Labs."I Firmly Believe That This Collaboration Will Lead To The Discovery Of New Pronectins That Must Be Considered A New Generation Medicine And Will Pave The Way For The Treatment Of Still Incurable Diseases", Said Prof. Giuseppe Nistic
